Skip to main content

IDWeek 2022 Main banner

Tweets by IDWeek 2022

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Back

Charles A. DeRyke, PharmD

Director
Merck Research Laboratories

Disclosure(s): Merck & Co., Inc. Merck Research Laboratories: Stocks/Bonds

Poster(s):

624 - Probability of Target Attainment of Ceftolozane/Tazobactam Among Adult Patients with Hospital-Acquired Pneumonia/Ventilator-Associated Pneumonia Secondary to Pseudomonas aeruginosa in Latin America
Thursday, October 20, 2022
12:15 PM – 1:30 PM US ET
1670 - Activity of Ceftolozane/Tazobactam and Comparators Against Clinical MDR and DTR Pseudomonas aeruginosa isolates – SMART United States 2018-2020
Saturday, October 22, 2022
12:15 PM – 1:30 PM US ET
1671 - Activity of Imipenem/Relebactam and Comparators Against Gram-Negative MDR and DTR Pathogens from Patients with Respiratory and Bloodstream Infections – SMART United States 2018-2020
Saturday, October 22, 2022
12:15 PM – 1:30 PM US ET
1674 - Trends in Antimicrobial Susceptibility to Ceftolozane/Tazobactam and Comparators of Pseudomonas aeruginosa from Patients with Respiratory Tract Infections in Five Latin American Countries – SMART 2017-2020
Saturday, October 22, 2022
12:15 PM – 1:30 PM US ET
2051 - Relebactam enhances Imipenem activity across the Imipenem susceptibility spectrum among Pseudomonas aeruginosa isolates collected in the United States--SMART 2018-2020
Saturday, October 22, 2022
12:15 PM – 1:30 PM US ET